Metachromatic leukodystrophy (MLD) is a rare and severe genetic disease. Inhibition of cerebroside sulfotransferase (CST) has been proposed as a promising new therapeutic strategy for the treatment of MLD. CST catalyzes the transfer of a sulfate group from the coenzyme 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to cerebroside yielding cerebroside sulfate and adenosine-3',5'-diphosphate (PAP).
View Article and Find Full Text PDF